Introduction. More attention is drawn to Candida spp. blood infections and its frequency especially in the development of intervention treatment technologies and the increasfng number of immunosuppressive patients. Our aim was to determine the Candida species, clinical indicators, patient outcomes and to identify risk factors interfaces in C. albicans and C. non-albicans for patients with candidemia, who were treated in intensive care unit (ICU) and those who had not been treated in ICU.
EN